Publications by authors named "S D Conzen"
Purpose: Glucocorticoid receptor (GR) activity may mediate chemoresistance in advanced triple-negative breast cancer (TNBC). Preclinical studies demonstrate that GR antagonism can augment the effect of taxanes in TNBC models. We hypothesized that pretreatment with mifepristone, a potent GR antagonist, would enhance nab-paclitaxel efficacy in advanced TNBC.
View Article and Find Full Text PDFUnderstanding how subcellular structures and events shape tissue-wide phenomena remains a central challenge in biology. We present Multiscale Cleared Tissue Axially Swept Light-Sheet Microscopy (MCT-ASLM), a platform combining cm-scale imaging with targeted high-resolution interrogation of intact tissues in human-guided or autonomous modes. Capable of capturing fields of view up to 21 mm at micron-scale resolution, MCT-ASLM can seamlessly transition to submicron (~300 nm) isotropic resolution for targeted imaging.
View Article and Find Full Text PDFArticle Synopsis
- In early-stage triple-negative breast cancer (TNBC), high glucocorticoid receptor (GR) expression is linked to poor outcomes, potentially due to an immunosuppressed tumor microenvironment.
- A study of 47 patients showed that high GR expression correlated with increased levels of immunosuppressive FOXP3+ regulatory T cells and BATF3+ immune cells, but not significantly with CD8+ T cell infiltration.
- The findings suggest that high GR expression may contribute to a more immunosuppressed state in TNBC, which could explain worse prognoses for patients with GR-positive tumors.
Article Synopsis
- High glucocorticoid receptor (GR) levels in ovarian cancer are linked to poor prognosis and can inhibit the effectiveness of chemotherapy.
- In a study, adding a selective GR modulator (SGRM) to chemotherapy improved progression-free survival (PFS) in one out of six ovarian cancer patient-derived models, specifically the one least sensitive to carboplatin.
- The variability in response suggests the need for identifying specific biomarkers to predict which patients would benefit from SGRM therapy alongside chemotherapy in treating high-grade serous ovarian cancer.